| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,630 | 1,650 | 16:39 |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | JUNSHI BIO Repurchases 170,400 Shrs on Wed for HKD2.3688 million | 1 | AASTOCKS | ||
| Di | JUNSHI BIO Repurchases 281,400 Shares for Approx. HKD4.01 million | 2 | AASTOCKS | ||
| Mo | JUNSHI BIO Repurchases 303,000 Shares on Mon for HKD4.3M | 1 | AASTOCKS | ||
| Mo | JUNSHI BIO (01877): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| Mo | JUNSHI BIO Tuoyi Urothelial Carcinoma Indication Included in National Reimbursement Drug List | 1 | AASTOCKS | ||
| Mo | JUNSHI BIO (01877): VOLUNTARY ANNOUNCEMENT - NEW INDICATION OF TUOYI HAS BEEN INCLUDED IN THE NATIONAL REIMBURSEMENT DRUG LIST | 1 | HKEx | ||
| 30.10. | JUNSHI BIO First Patient Dosed in Phase III Trial of JS207 Combined With JS007 for Advanced Hepatocellular Carcinoma | 1 | AASTOCKS | ||
| SHANGHAI JUNSHI BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 30.10. | JUNSHI BIO 9M Loss Narrows to RMB149 Million | 1 | AASTOCKS | ||
| 29.10. | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON CASH MANAGEMENT BY USING TEMPORARILY IDLE ... | 3 | HKEx | ||
| 29.10. | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* 2026 THIRD QUARTERLY REPORT | 3 | HKEx | ||
| 29.10. | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON THE CONVENING OF THE 2026 THIRD QUARTERLY ... | 1 | HKEx | ||
| 29.10. | JUNSHI BIO (01877): VOLUNTARY ANNOUNCEMENT - COMPLETION OF FIRST PATIENT DOSING IN THE PHASE III CLINICAL TRIAL OF JS207 IN COMBINATION WITH JS007 FOR ... | 1 | HKEx | ||
| 29.10. | Junshi Biosciences Announces the Completion of First Patient Dosing in the Phase 3 Clinical Trial of JS207 in Combination with JS007 for the First-Line Treatment of Advanced Hepatocellular Carcinoma | 514 | GlobeNewswire (Europe) | SHANGHAI, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the... ► Artikel lesen | |
| 29.10. | Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma | 520 | GlobeNewswire (Europe) | SHANGHAI, China, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated... ► Artikel lesen | |
| 28.10. | JUNSHI BIO (01877): VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF THE SUPPLEMENTAL NEW DRUG APPLICATION OF TORIPALIMAB INJECTION (SUBCUTANEOUS INJECTION) FOR ... | 1 | HKEx | ||
| 28.10. | JUNSHI BIO (01877): VOLUNTARY ANNOUNCEMENT - REGULAR APPROVAL FOR TORIPALIMAB FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA WHO ... | 2 | HKEx | ||
| 28.10. | Junshi Biosciences Announces Final Analysis Results of the Phase 3 NEOTORCH Study at ESMO Congress 2026 | 570 | GlobeNewswire (Europe) | Perioperative toripalimab plus chemotherapy demonstrated significant and durable improvements in event-free survival and overall survival in patients with resectable stage II-III non-small cell lung... ► Artikel lesen | |
| 26.10. | JUNSHI BIO JS203 Combined With Chemotherapy Phase III Clinical Study Completes First Patient Dosing | 3 | AASTOCKS | ||
| 24.10. | Junshi Biosciences Announces Completion of First Patient Dosing in the Phase 3 Clinical Trial of JS203 in Combination with Chemotherapy for the Treatment of Diffuse Large B-cell Lymphoma | 733 | GlobeNewswire (Europe) | SHANGHAI, China, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated... ► Artikel lesen | |
| 23.10. | JUNSHI BIO (01877): VOLUNTARY ANNOUNCEMENT - COMPLETION OF FIRST PATIENT DOSING IN THE PHASE III CLINICAL TRIAL OF JS203 IN COMBINATION WITH CHEMOTHERAPY ... | - | HKEx |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 45,200 | 0,00 % | QIAGEN N.V.: QIAGEN Shareholders Overwhelmingly Approve Jonathan M. Pratt as Managing Director | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that shareholders overwhelmingly approved the appointment of Jonathan M. Pratt as a Managing Director and member of the QIAGEN... ► Artikel lesen | |
| CG ONCOLOGY | 83,00 | +3,75 % | Guggenheim raises CG Oncology stock price target on trial results | ||
| SUMMIT THERAPEUTICS | 10,680 | +1,71 % | Summit Therapeutics (SMMT) Is Losing Wall Street's Confidence | ||
| PRAXIS PRECISION MEDICINES | 318,84 | +4,52 % | Guggenheim hebt Kursziel für Praxis Precision Medicines auf 1.050 $ an - Kaufempfehlung bestätigt | ||
| RECURSION PHARMACEUTICALS | 2,860 | +5,15 % | Recursion auf der Jefferies Global Healthcare Conference: KI-Pipeline gewinnt an klinischer Dynamik | ||
| KYMERA THERAPEUTICS | 120,30 | -1,00 % | Kymera International Appoints Willson Ropp as Chief Executive Officer | Experienced specialty materials executive brings more than 30 years of leadership experience across global manufacturing, operational excellence, business integration, and long-term value... ► Artikel lesen | |
| BEAM THERAPEUTICS | 21,880 | +4,14 % | Beam Therapeutics auf UBS-Konferenz: Forcierte Plattformstrategie und BLA-Antrag für Sichelzelltherapie in Sicht | ||
| BIONTECH | 75,35 | -1,63 % | BioNTech-Aktie: Totes Kapital? | Die Aktie von BioNTech bleibt trotz des rückläufigen Impfstoffgeschäfts ein spannender Titel am Aktienmarkt. Anleger richten ihren Blick zunehmend auf die milliardenschwere Forschungspipeline im Bereich... ► Artikel lesen | |
| EVOTEC | 2,728 | 0,00 % | Evotec-Aktie: Gewinn- und Umsatzrekord? | Die Aktie des Hamburger Wirkstoffforschers Evotec bleibt ein spannender, aber risikoreicher Titel am deutschen Aktienmarkt. Nach schwierigen Monaten sorgen erste operative Fortschritte, neue Partnerschaften... ► Artikel lesen | |
| ERASCA | 14,140 | +2,61 % | Erasca, Bristol Myers Squibb Partner To Study Combination Therapy In Pancreatic Cancer | NEW YORK CITY (dpa-AFX) - Erasca, Inc. (ERAS) announced a clinical trial collaboration with Bristol Myers Squibb (BMY) to evaluate ERAS-0015, Erasca's investigational pan-RAS molecular glue... ► Artikel lesen | |
| MODERNA | 176,48 | -1,56 % | Moderna nach 300 % Rallye: Droht jetzt eine größere Korrektur? | Seit August verzeichnete Moderna einen deutlichen Kursanstieg, auf den zuletzt eine Zwischenkorrektur folgte. Die bisher intakte Folge höherer Hochs und Tiefs sowie die zuletzt verteidigte 50-Tage-Linie... ► Artikel lesen | |
| DYNE THERAPEUTICS | 16,405 | +2,40 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) | - Data from a pooled dose group of participants initially enrolled in the multiple ascending dose (MAD) portion of ACHIEVE showed functional improvement versus baseline, versus placebo and versus... ► Artikel lesen | |
| COGENT BIOSCIENCES | 28,390 | +1,94 % | Cogent Biosciences auf Jefferies-Konferenz: Markteinführungspläne hängen an Bezuclastinib | ||
| VOR BIOPHARMA | 18,150 | +1,79 % | Vor Biopharma auf der Jefferies Global Healthcare Conference: Finanzstarker Vorstoß bei Autoimmunerkrankungen | ||
| ABSCI | 8,380 | +2,38 % | Absci auf der Jefferies Global Healthcare Conference: Milliardenmarkt für neuartigen Haarausfall-Wirkstoff im Fokus |